Tarsus Pharmaceuticals (TARS) will present four distinct data sets highlighting the global prevalence and real-world patient burden of Demodex ...

Tarsus Pharmaceuticals, Inc. (TARS) closed the last trading session at $50.40, gaining 10.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price ...

Tarsus Pharmaceuticals, Inc. (TARS) shares ended the last trading session 10.6% higher at $43.87. The jump came on an impressive volume with a higher-than-average number of shares changing hands ...

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03 ...

Tarsus Pharmaceuticals announced a $100 million underwritten public offering of its common stock, with a 30-day underwriter option for additional shares. Tarsus Pharmaceuticals, Inc. has announced ...

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States.

Tarsus Pharmaceuticals, Inc.’s TARS share price has dipped by 6.95%, which has investors questioning if this is right time to buy.

Business may be picking up for locally-based drugmakers just a year after the local sector was showing declines.

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03 ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...